KDIGO Guideline Summary: Management of Proteinuria in Young Adults with CKD

Pharmacologic Initiation and Dose Optimization

Situational Contra‑indications to RAS Blockade

Blood‑Pressure Targets

Laboratory Monitoring and Tolerance Thresholds

Sodium and Protein Dietary Recommendations

Proteinuria Reduction Goals

Adjunctive Pharmacologic Therapies (Diabetes‑Specific)

Hyperkalemia Management While Preserving RAS Blockade

Diuretic Strategy for Edema

Nephrology Referral Criteria

Common Pitfalls to Avoid

Patient Education and Sick‑Day Management

Lifestyle Modifications

Initiating ACE Inhibitors in Patients with Proteinuria

Primary Indications for ACE Inhibitor Initiation

• The American Journal of Kidney Diseases recommends starting an ACE inhibitor immediately in any patient with proteinuria ≥1 g/day, regardless of blood pressure status, and strongly consider starting if proteinuria is between 0.5-1 g/day 8, 9
• The Kidney International guideline suggests using ACE inhibitor or ARB to maximally tolerated dose as first-line therapy for patients with hypertension and any level of proteinuria 10, 9
• The American Journal of Kidney Diseases suggests ACE inhibitor or ARB treatment for patients with proteinuria 0.5-1 g/day, even without hypertension 8, 11, 12
• Consider ACE inhibitor treatment in children with proteinuria 0.5-1 g/day per 1.73 m² 8, 11

Critical Exception: When to Delay or Avoid

• The Kidney International guideline advises against starting ACE inhibitors in patients presenting with abrupt onset nephrotic syndrome, particularly if minimal change disease is suspected, as these drugs can cause acute kidney injury in this setting 10, 9
• Delay ACE inhibitor initiation in patients expected to be rapidly responsive to immunosuppression without hypertension 10, 9

Dosing Strategy

• The Kidney International guideline recommends uptitrating ACE inhibitors to maximally tolerated or allowed dose, not just to blood pressure control 10, 8, 9
• The goal is proteinuria reduction to <1 g/day, not just blood pressure control 10, 9

Blood Pressure Targets When Using ACE Inhibitors

• The Kidney International guideline targets systolic BP <120 mmHg in most adult patients with proteinuria using standardized office measurement 10, 9, 13
• In IgA nephropathy, target 130/80 mmHg if proteinuria <1 g/day; 125/75 mmHg if proteinuria ≥1 g/day 8, 11

Essential Monitoring Parameters

• The Kidney International guideline accepts up to 30% increase in serum creatinine after starting ACE inhibitor, which is hemodynamic and expected, not a reason to stop therapy 10, 9, 13, 14
• Stop ACE inhibitor only if kidney function continues to worsen beyond 30% increase or refractory hyperkalemia develops 10, 9

Synergistic Supportive Measures

• The Kidney International guideline mandates dietary sodium restriction to <2.0 g/day, as it enhances the antiproteinuric effect of ACE inhibitors 10, 9, 13, 15, 14
• Additional lifestyle modifications include weight normalization, smoking cessation, and regular exercise 10, 9, 14

Managing Resistant Proteinuria

• If proteinuria persists despite maximized ACE inhibitor dose, consider adding a thiazide-like diuretic, mineralocorticoid receptor antagonist, or SGLT2 inhibitor in diabetic patients 9, 15, 10, 13

Common Pitfalls to Avoid

• Do not discontinue ACE inhibitors prematurely due to modest creatinine elevation, as this removes critical renoprotection 13, 14, 10, 9
• Do not combine ACE inhibitor with ARB, as this increases adverse effects without additional benefit in most patients 13
• Counsel patients to hold ACE inhibitors during intercurrent illnesses with risk of volume depletion 10, 9, 13

Timeline for Reassessment

• Optimize ACE inhibitor therapy for 3-6 months before considering additional immunosuppressive therapy 8, 11, 12
• If proteinuria remains >1 g/day after 3-6 months of optimized supportive care, consider adding immunosuppression 8, 11, 12